Case Summary:     

Behind every breakthrough in medicine is a dedicated researcher turning data into hope. One such researcher—a senior clinical research coordinator specializing in epilepsy—has recently secured EB-2 NIW (National Interest Waiver) approval, a recognition of the national value of her work. From managing multi-center studies to guiding therapeutic advancements, her work sits at the intersection of clinical innovation and patient care.

Pioneering Studies in Drug-Resistant Epilepsy

This researcher’s focus is on improving outcomes for individuals with severe forms of epilepsy, including those unresponsive to conventional treatments. Her work has been instrumental in clinical investigations targeting New Onset Refractory Status Epilepticus (NORSE) and Febrile Infection-Related Epilepsy Syndrome (FIRES)—conditions marked by high mortality and limited treatment options.

Through collaborations with intensive care teams across multiple institutions, she has contributed to data-driven analyses of emerging therapies, including immunomodulatory treatments and neuromodulation strategies, such as responsive neurostimulation (RNS). Her research has helped clarify the efficacy of non-invasive alternatives for patients for whom surgical resection is not viable, and has guided the adoption of new standards of care in drug-resistant epilepsy management.

An Impact Felt Across the Field

To date, the petitioner has authored four peer-reviewed journal articles and six abstracts, with her work published in high-impact journals like Epilepsia, Frontiers in Neurology, and Journal of Clinical Neurophysiology. Her publications have earned 46 citations, and several rank in the top 10% or even top 1% of most-cited articles in the field of Neuroscience & Behavior for their year of publication.

Her study on RNS as a treatment for epilepsy comorbid with autism spectrum disorder has been cited as a model for safe and effective alternatives to resective surgery. These findings have already been leveraged by researchers investigating targeted therapies for pediatric and adult epilepsy cases globally.

A Thought Leader Recognized by Her Peers

The client’s impact extends beyond publication metrics. She has served as principal data coordinator and study lead for multiple multi-center trials, working across global epilepsy networks to collect biospecimens, monitor neurological outcomes, and track treatment efficacy. Her record of progress, including studies focused on predictive EEG algorithms and wearable seizure warning systems, continues to influence how technology and medicine intersect in neurology.

Independent Endorsement of National Value

A leading neurology expert who has collaborated with the petitioner wrote:

“[Client’s] research fosters global collaboration, which will ultimately improve diagnosis and treatment for rare neurological disorders, advancing patient care and understanding of these complex conditions.”

This endorsement underscores the unique blend of coordination, clinical insight, and innovation that defines her role in advancing epilepsy care.

Overcoming Challenges and Securing Approval

Despite the issuance of a Request for Evidence (RFE) during the review process, NAILG was able to reaffirm the strength of the case by demonstrating that the petitioner:

• Is engaged in an endeavor of substantial merit and national importance, advancing both health outcomes and cost efficiency;
• Is well positioned through training, peer-reviewed contributions, and recognized expertise to continue this work;
• It would be beneficial to waive the labor certification requirement, allowing the continuation of impactful research that serves the broader public good.

Filed under premium processing on January 16, 2025, and approved on July 1, this petition reflects the value of deep clinical insight combined with a vision for scalable, patient-centered care.

This approval is not just a personal milestone—it’s a testament to how collaborative, clinically grounded research can reshape care for some of the most vulnerable patients. NAILG proudly celebrates this success, recognizing the researcher’s role in pushing forward the boundaries of treatment for drug-resistant epilepsy.